Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer’s Biomarkers For Disease Progression Will Be A Hard Road, Experts Say

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A panel of experts discussing challenges in researching disease-progression biomarkers for Alzheimer’s agreed that the heterogeneity and evolving nature of the disease complicate the task and may require large panels of biomarkers – a potentially costly and invasive solution.

You may also be interested in...



Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s

It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.

Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio

The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.

Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel